This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Survey Conducted Within The Academic Research Community Ignites Debate Around Data Reproducibility And Quality Standards In Translational Research

Stocks in this article: SIAL

ST. LOUIS, Sept. 18, 2013 /PRNewswire/ --  Sigma-Aldrich Corporation (NASDAQ: SIAL) today released a report on the state of academic translational research, a rapidly expanding field in which academic scientists aim to "translate" their laboratory discoveries to patient benefit. The first-of-its-kind survey was conducted by Sigma-Aldrich and the Association for the Advancement of Science (AAAS) and was completed by more than 600 academic scientists who identified their research as translational. 

An important finding was the differing perspectives among the scientists about whether academic translational research should be held to a higher standard of practice and which best practices should be adopted to assure that experiments are reproducible. Reproducibility of experiments is particularly critical to the success of translational researchers, whose goal is to deliver products for patient use. This is a key criterion of funding sources that provide subsequent milestone investments.

"Sigma-Aldrich has shown its commitment to the translational research community by supporting opportunities and innovations generated by research institutions, and delivering scientific expertise all along the drug discovery chain, from target identification to enabling clinical trials," said Amanda Halford, Vice President of Academic Research at Sigma-Aldrich. "We also believe in the importance of alliances that permit biologists and chemists in academia and non-profits to work closely with private industry and government agencies to bring the most promising research out of the so-called 'valley of death.'"

"Sigma-Aldrich conducted this survey," Halford added, "to help understand how we can maximize the potential of translational research. That means finding out what works, identifying what does not, and stimulating debate about possible solutions."

Reproducibility has become an important issue in part because of recent adverse commentary in industry reviews. A team at Bayer HealthCare in Germany found that only 25% of published pre-clinical studies it analyzed could be validated so that projects could continue 1. A team at Amgen later found that the findings of only 11% of "landmark" hematology and oncology-related studies were confirmed in its laboratories 2. Earlier this year, Nature released a reproducibility checklist that must accompany manuscript submissions, but Sigma-Aldrich's Translational Research Team believes lab practices beyond the contents of this checklist may also need to be addressed.

Survey respondents are in agreement that some type of action is required to ensure reproducibility above and beyond what is currently being done. For example, 55% said they would be willing to use standardized or validated reagents to ensure that their research is perceived as reproducible. Additionally, The Sigma-Aldrich Survey Report indicates that 97% of the respondents are willing to take some kind of action, making it clear that the translational research community is interested in addressing reproducibility.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,066.84 +36.63 0.20%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs